Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo

C Kramers, M N Hylkema, M C van Bruggen, R van de Lagemaat, H B Dijkman, K J Assmann, R J Smeenk, J H Berden, C Kramers, M N Hylkema, M C van Bruggen, R van de Lagemaat, H B Dijkman, K J Assmann, R J Smeenk, J H Berden

Abstract

Histones can mediate the binding of DNA and anti-DNA to the glomerular basement membrane (GBM). In ELISA histone/DNA/anti-DNA complexes are able to bind to heparan sulfate (HS), an intrinsic constituent of the GBM. We questioned whether histone containing immune complexes are able to bind to the GBM, and if so, whether the ligand in the GBM is HS. Monoclonal antibodies (mAbs) complexed to nucleosomal antigens and noncomplexed mAbs were isolated from culture supernatants of four IgG anti-nuclear mAbs. All noncomplexed mAbs showed strong anti-nucleosome reactivity in ELISA. One of them showed in addition anti-DNA reactivity in noncomplexed form. The other three mAbs only showed anti-DNA reactivity when they were complexed to nucleosomal antigens. After renal perfusion a fine granular binding of complexed mAbs to the glomerular capillary wall and activation of complement was observed in immunofluorescence, whereas noncomplexed mAbs did not bind. Immuno-electron microscopy showed binding of complexes to the whole width of the GBM. When HS in the GBM was removed by renal heparinase perfusion the binding of complexed mAb decreased, but did not disappear completely. We conclude that anti-nucleosome mAbs, which do not bind DNA, become DNA reactive once complexed to nucleosomal antigens. These complexed mAbs can bind to the GBM. The binding ligand in the GBM is partly, but not solely, HS. Binding to the GBM of immune complexes containing nucleosomal material might be an important event in the pathogenesis of lupus nephritis.

References

    1. J Immunol Methods. 1994 Mar 29;170(1):93-102
    1. Clin Nephrol. 1994 Jan;41(1):10-7
    1. J Exp Med. 1971 Sep 1;134(3 Pt 2):169s-179s
    1. J Clin Invest. 1977 Jan;59(1):90-6
    1. Arthritis Rheum. 1979 Mar;22(3):226-35
    1. J Exp Med. 1982 Apr 1;155(4):1210-5
    1. Connect Tissue Res. 1982;9(4):247-8
    1. Adv Immunol. 1982;33:167-240
    1. J Immunol. 1986 May 15;136(10):3785-92
    1. J Immunol. 1987 May 1;138(9):2883-9
    1. J Immunol. 1988 Mar 15;140(6):1816-22
    1. N Engl J Med. 1988 Jun 2;318(22):1431-6
    1. J Immunol. 1988 Jun 1;140(11):3786-92
    1. J Immunol. 1989 May 1;142(9):3076-82
    1. Arthritis Rheum. 1989 May;32(5):513-22
    1. J Exp Med. 1989 Jun 1;169(6):1879-94
    1. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4669-73
    1. Methods Enzymol. 1989;170:3-14
    1. Res Immunol. 1989 Jun-Aug;140(5-6):595-612
    1. Biochem J. 1989 Dec 1;264(2):457-65
    1. Arthritis Rheum. 1990 May;33(5):634-43
    1. J Clin Invest. 1990 Jul;86(1):69-74
    1. Immunol Today. 1990 Jul;11(7):232-4
    1. J Immunol Methods. 1990 Aug 28;132(1):91-101
    1. Clin Exp Immunol. 1990 Nov;82(2):268-74
    1. J Autoimmun. 1990 Oct;3(5):531-45
    1. J Clin Invest. 1991 Aug;88(2):680-90
    1. J Immunol. 1992 Mar 1;148(5):1561-9
    1. Kidney Int. 1992 Jan;41(1):115-23
    1. Clin Exp Immunol. 1992 Dec;90(3):453-8
    1. Kidney Int. 1992 Dec;42(6):1363-71
    1. Kidney Int. 1993 Feb;43(2):454-63
    1. Lab Invest. 1993 Feb;68(2):164-73
    1. Arthritis Rheum. 1993 Apr;36(4):552-60
    1. J Clin Invest. 1993 Apr;91(4):1687-96
    1. J Exp Med. 1993 May 1;177(5):1367-81
    1. Clin Exp Immunol. 1993 Jul;93(1):34-8
    1. Exp Nephrol. 1993 Jul-Aug;1(4):224-8

Source: PubMed

3
Iratkozz fel